Drug Safety Data

Drug Safety Data
Author :
Publisher : Jones & Bartlett Learning
Total Pages : 332
Release :
ISBN-10 : 9780763769123
ISBN-13 : 0763769126
Rating : 4/5 (126 Downloads)

Book Synopsis Drug Safety Data by : Michael J. Klepper

Download or read book Drug Safety Data written by Michael J. Klepper and published by Jones & Bartlett Learning. This book was released on 2011 with total page 332 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides pharmaceutical scientists, researchers and technicians with an accessible, practical framework for the analysis, summary and interpretation of drug safety data. The only guide of its kind, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is an invaluable reference for premarketing risk assessment. This unique resource enhances the ability of pharmaceutical professionalsùthose with and without clinical trainingùto determine the risk of a drug or biologic­ ahead of its release, thereby reducing unnecessary jeopardy to the patient. Authors Dr. Michael Klepper and Dr. Barton Cobert, who together bring decades of pharmaceutical research and drug safety expertise, discuss how quality planning, safety training and data standardization result in significant cost, time and resource savings. Through illustrative, step-by-step instruction, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides the definitive guide to drug safety data analysis and reporting. Key features include: Step-by-step instruction on how to analyze, summarize and interpret safety data for mandatory governmental safety reports Pragmatic tipsàand mistakes to avoid Simple explanations of what safety data are collected, and what the data mean Practical approaches to determining a drug effect and understanding its clinical significance Guidance for determining risk throughout the lifecycle of a drug, biologic or nutraceutical Examples of user-friendly data displays that enhance safety signal identification Ways to improve data quality and reduce the time, resources and costs involved in mandatory safety reporting Relevant material for the required training of drug safety/pharmacovigilance professionals SPECIAL FEATURE: Actual examples of an Integrated Analysis of Safety (IAS) -used in the preparation of the Integrated Summary of Safety (ISS) and the Summary of Clinical Safety (SCS) reports -, and the Periodic Safety Update Report (PSUR)


Drug Safety Data Related Books

Drug Safety Data
Language: en
Pages: 332
Authors: Michael J. Klepper
Categories: Medical
Type: BOOK - Published: 2011 - Publisher: Jones & Bartlett Learning

GET EBOOK

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides pharmaceutical scientists, researchers and technicians with an accessible,
Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk
Language: en
Pages: 332
Authors: Michael J. Klepper
Categories: Medical
Type: BOOK - Published: 2010-09-15 - Publisher: Jones & Bartlett Publishers

GET EBOOK

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk was selected for The First Clinical Research Bookshelf - Essential reading for clini
Drug Safety Data
Language: en
Pages: 312
Authors: Michael J. Klepper
Categories: Health risk assessment
Type: BOOK - Published: 2011 - Publisher:

GET EBOOK

Evidence Synthesis and Meta-analysis for Drug Safety
Language: en
Pages: 0
Authors: Council for International Organizations of Medical Sciences (CIOMS)
Categories: Drugs
Type: BOOK - Published: 2016 - Publisher: World Health Organization

GET EBOOK

At any point in the drug development process, systematic reviews and meta-analysis can provide important information to guide the future path of the development
The Future of Drug Safety
Language: en
Pages: 347
Authors: Institute of Medicine
Categories: Medical
Type: BOOK - Published: 2007-03-27 - Publisher: National Academies Press

GET EBOOK

In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess th